Commission Decision

of 18 December 2008

on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2009 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council on substances that deplete the ozone layer

(notified under document number C(2008) 8398)

(Only the Dutch, English, French, German, Italian, Slovenian and Spanish texts are authentic)

(2009/52/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 2037/2000 of the European Parliament and of the Council of 29 June 2000 on substances that deplete the ozone layer [1], and in particular Article 3(1) thereof,

Whereas:

(1) The Community has already phased out the production and consumption of chlorofluorocarbons, other fully halogenated chlorofluorocarbons, halons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbon and bromochloromethane.

(2) Each year the Commission is required to determine essential uses for these controlled substances, the quantities that may be used and the companies that may use them.

(3) Decision IV/25 of the Parties to the Montreal Protocol on substances that deplete the ozone layer, hereinafter "the Montreal Protocol", sets out the criteria used by the Commission for determining any essential uses and authorises the production and consumption necessary to satisfy essential uses of controlled substances in each Party.

(4) The Parties to the Montreal Protocol authorised the production in the European Community of 22 tonnes of chlorofluorocarbons (CFCs) in 2009 for the manufacturing and use of metered-dose inhalers (MDIs) qualifying for essential uses of CFCs as defined in Decision IV/25.

(5) Decision XIX/18 of the Parties to the Montreal Protocol authorises the production and consumption necessary to satisfy essential uses of controlled substances listed in Annexes A, B and C (Group II and III substances) of the Montreal Protocol for laboratory and analytical uses as listed in Annex IV to the report of the Seventh Meeting of the Parties, subject to the conditions set out in Annex II to the report of the Sixth Meeting of the Parties, as well as Decisions VII/11, XI/15 and XV/5 of the Parties to the Montreal Protocol. Decision XVII/10 of the Parties to the Montreal Protocol authorises the production and consumption of the controlled substance listed in Annex E of the Montreal Protocol necessary to satisfy laboratory and analytical critical uses of methyl bromide.

(6) Pursuant to paragraph 3 of Decision XII/2 of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free MDIs, all Member States have notified the United Nations Environment Programme the active ingredients for which chlorofluorocarbons (CFCs) are no longer essential for the manufacture of MDIs for placing on the market of the European Community.

(7) Article 4(4)(i)(b) of Regulation (EC) No 2037/2000 prevents CFCs from being used and placed on the market unless they are considered essential under the conditions described in Article 3(1) of that Regulation. These non-essentiality determinations have therefore reduced the demand for CFCs used in MDIs that are placed on the market of the European Community. In addition, Article 4(6) of Regulation (EC) No 2037/2000 prevents CFC-MDI products being imported and placed on the market unless the CFCs in these products are considered essential under the conditions described in Article 3(1).

(8) The Commission has published a notice [2] to those companies in the Member States that request consideration by the Commission for the use of controlled substances for essential uses in the Community in 2009 and has received declarations on intended essential uses of controlled substances for 2009.

(9) The measures provided for in this Decision are in accordance with the opinion of the Management Committee established by Article 18(1) of Regulation (EC) No 2037/2000,

HAS ADOPTED THIS DECISION:

Article 1

1. The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) subject to Regulation (EC) No 2037/2000 which may be used for essential medical uses in the Community in 2009 shall be 21360,00 ozone depleting potential (ODP) kilograms.

2. The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) and Group II (other fully halogenated chlorofluorocarbons) subject to Regulation (EC) No 2037/2000 which may be used for essential laboratory and analytical uses in the Community in 2009 shall be 60280,8 ODP kilograms.

3. The quantity of controlled substances of Group III (halons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory and analytical use in the Community in 2009 shall be 115,7 ODP kilograms.

4. The quantity of controlled substances of Group IV (carbon tetrachloride) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory and analytical uses in the Community in 2009 shall be 129390,8 ODP kilograms.

5. The quantity of controlled substances of Group V (1,1,1-trichloroethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory and analytical uses in the Community in 2009 shall be 355,65 ODP kilograms.

6. The quantity of controlled substances of Group VI (methyl bromide) subject to Regulation (EC) No 2037/2000 that may be used for laboratory and analytical critical uses in the Community in 2009 shall be 36,3 ODP kilograms.

7. The quantity of controlled substances of Group VII (hydrobromofluorocarbons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory and analytical uses in the Community in 2009 shall be 57,96 ODP kilograms.

8. The quantity of controlled substances of group IX (bromochloromethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory and analytical uses in the Community in 2009 shall be 11,088 ODP kilograms.

Article 2

The chlorofluorocarbon metered-dose inhalers listed in Annex I shall not be placed on markets where the competent authority has determined chlorofluorocarbons for metered-dose inhalers on those markets to be non-essential.

Article 3

During the period 1 January to 31 December 2009 the following rules shall apply:

1. The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II.

2. The allocation of essential laboratory and analytical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III.

3. The allocation of essential laboratory and analytical use quotas for halons shall be to the companies indicated in Annex IV.

4. The allocation of essential laboratory and analytical use quotas for carbon tetrachloride shall be to the companies indicated in Annex V.

5. The allocation of essential laboratory and analytical use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI.

6. The allocation of laboratory and analytical critical use quotas for methyl bromide shall be to the companies indicated in Annex VII.

7. The allocation of essential laboratory and analytical use quotas for hydrobromofluorocarbons shall be to the companies indicated in Annex VIII.

8. The allocation of essential laboratory and analytical use quotas for bromochloromethane shall be to the companies indicated in Annex IX.

9. The essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, other fully halogenated chlorofluorocarbons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbons and bromochloromethane and the laboratory and analytical critical use quotas for methyl bromide shall be as set out in Annex X.

Article 4

This Decision shall apply from 1 January 2009 and shall expire on 31 December 2009.

Article 5

This Decision is addressed to the following undertakings:

Acros Organics bvba

Janssen Pharmaceuticalaan 3a

B-2440 Geel

Airbus France

316, route de Bayonne

F-31300 Toulouse

Carlo Erba Réactifs-SDS

Z.I. de Valdonne, BP 4

F-13124 Peypin

Chiesi Farmaceutici SpA

Via Palermo 26/A

I-43100 Parma

CNRS — Groupe de physique des solides

Université Paris 7 Denis Diderot et Paris 6

Pierre et Marie Curie

F-75251 Paris Cedex 5

Harp International

Gellihirion Industrial Estate Rhondda,

Cynon Taff

Pontypridd CF37 5SX

UNITED KINGDOM

Honeywell Specialty Chemicals

Wunstorfer Stra?e 40

Postfach 10 02 62

D-30918 Seelze

Ineos Fluor Ltd

PO Box 13, The Heath

Runcorn Cheshire WA7 4QF

UNITED KINGDOM

Institut scientifique de service public

Rue du Chéra 200

B-4000 Liège

LGC Standards GmbH

Mercatorstra?e 51

D-46485 Wesel

Mallinckrodt Baker BV

Teugseweg 20

7418 AM Deventer

Nederland

Merck KGaA

Frankfurter Stra?e 250

D-64271 Darmstadt

Mikro + Polo d.o.o.

Zagreb?ka cesta 22

SI-2000 Maribor

Ministry of Defense

Defence Fuel Lubricants and Chemicals

PO Box 10 000

1780 CA Den Helder

Nederland

Panreac Química SA

Pol. Ind. Pla de la Bruguera, C/Garraf, 2

E-08211 Castellar del Vallès

Barcelona

Sigma Aldrich Chimie SARL

80, rue de Luzais

L’Isle d’Abeau Chesnes

F-38297 Saint-Quentin-Fallavier

Sigma Aldrich Company

The Old Brickyard, New Road

Gillingham SP8 4XT

UNITED KINGDOM

Sigma Aldrich Laborchemikalien

Wunstorfer Stra?e 40

Postfach 10 02 62

D-30918 Seelze

Sigma Aldrich Logistik GmbH

Riedstra?e 2

D-89555 Steinheim

Solvay Organics GmbH

Hans-B?ckler-Allee 20

D-30173 Hannover

Tazzetti Fluids SRL

Corso Europa 600/a

I-10088 Volpiano (TO)

Valeas SpA Pharmaceuticals

Via Vallisneri 10

I-20133 Milano

Valvole Aerosol Research Italiana (VARI)

SpA — LINDAL Group Italia

Via del Pino 10

I-23854 Olginate (LC)

VWR ISAS

201, rue Carnot

F-94126 Fontenay-sous-Bois

Done at Brussels, 18 December 2008.

For the Commission

Stavros Dimas

Member of the Commission

[1] OJ L 244, 29.9.2000, p. 1.

[2] OJ C 114, 9.5.2008, p. 27.

--------------------------------------------------

ANNEX I

Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as "essential" under the Protocol when combined with following active ingredients:

LIST OF NON-ESSENTIAL SUBSTANCES

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp

Table 1

Short-acting beta agonist bronchodilators

Country | Salbutamol | Terbutaline | Fenoterol | Orciprenaline | Reproterol | Carbuterol | Hexoprenaline | Pirbuterol | Clenbuterol | Bitolterol | Procaterol |

Austria | X | X | X | X | X | X | X | X | X | X | X |

Belgium | X | X | X | X | X | X | X | X | X | X | X |

Bulgaria | X | X | X | X | X | X | X | X | X | X | X |

Cyprus | X | X | X | X | X | X | X | X | X | X | X |

Czech Republic | X | X | X | X | X | X | X | X | X | X | X |

Denmark | X | X | X | X | X | X | X | X | X | X | X |

Estonia | X | X | X | X | X | X | X | X | X | X | X |

Finland | X | X | X | X | X | X | X | X | X | X | X |

France | X | X | X | X | X | X | X | X | X | X | X |

Germany | X | X | X | X | X | X | X | X | X | X | X |

Greece | X | X | X | X | X | X | X | X | X | X | X |

Hungary | X | X | X | X | X | X | X | X | X | X | X |

Ireland | X | X | X | X | X | X | X | X | X | X | X |

Italy | X | X | X | X | X | X | X | X | X | X | X |

Latvia | X | X | X | X | X | X | X | X | X | X | X |

Lithuania | X | X | X | X | X | X | X | X | X | X | X |

Luxembourg | X | X | X | X | X | X | X | X | X | X | X |

Malta | X | X | X | X | X | X | X | X | X | X | X |

Netherlands | X | X | X | X | X | X | X | X | X | X | X |

Poland | X | X | X | X | X | X | X | X | X | X | X |

Portugal | X | X | X | X | X | X | X | X | X | X | X |

Romania | X | X | X | X | X | X | X | X | X | X | X |

Slovakia | X | X | X | X | X | X | X | X | X | X | X |

Slovenia | X | X | X | X | X | X | X | X | X | X | X |

Spain | X | X | X | X | X | X | X | X | X | X | X |

Sweden | X | X | X | X | X | X | X | X | X | X | X |

United Kingdom | X | X | X | X | X | X | X | X | X | X | X |

Table 2

Inhaled steroids

Country | Beclomethasone | Dexamethasone | Flunisolide | Fluticasone | Budesonide | Triamcinolone |

Austria | X | X | X | X | X | X |

Belgium | X | X | X | X | X | X |

Bulgaria | X | X | X | X | X | X |

Cyprus | X | X | X | X | X | X |

Czech Republic | X | X | X | X | X | X |

Denmark | X | X | X | X | X | X |

Estonia | X | X | X | X | X | X |

Finland | X | X | X | X | X | X |

France | X | X | X | X | X | X |

Germany | X | X | X | X | X | X |

Greece | X | X | X | X | X | X |

Hungary | X | X | X | X | X | X |

Ireland | X | | | X | | |

Italy | X | X | X | X | X | X |

Latvia | X | X | X | X | X | X |

Lithuania | X | X | X | X | X | X |

Luxembourg | X | X | X | X | X | X |

Malta | | | | X | X | |

Netherlands | X | X | X | X | X | X |

Poland | X | X | X | X | X | X |

Portugal | X | X | X | X | X | X |

Romania | X | X | X | X | X | X |

Slovakia | X | X | X | X | X | X |

Slovenia | X | X | X | X | X | X |

Spain | X | X | X | X | X | X |

Sweden | X | X | X | X | X | X |

United Kingdom | | | | X | | |

Table 3

Non-steroidal anti-inflammatories

Country | Cromoglicic acid | Nedrocromil |

Austria | X | X |

Belgium | X | X |

Bulgaria | X | X |

Cyprus | X | X |

Czech Republic | X | X |

Denmark | X | X |

Estonia | X | X |

Finland | X | X |

France | X | X |

Germany | X | X |

Greece | X | X |

Hungary | X | |

Ireland | | |

Italy | X | X |

Latvia | X | X |

Lithuania | X | X |

Luxembourg | X | |

Malta | | X |

Netherlands | X | X |

Poland | X | X |

Portugal | X | |

Romania | X | X |

Slovakia | X | X |

Slovenia | X | X |

Spain | X | X |

Sweden | X | X |

United Kingdom | X | X |

Table 4

Anticholinergic bronchodilators

Country | Ipratropium bromide | Oxitropium bromide |

Austria | X | X |

Belgium | X | X |

Bulgaria | X | X |

Cyprus | X | X |

Czech Republic | X | X |

Denmark | X | X |

Estonia | X | X |

Finland | X | X |

France | X | X |

Germany | X | X |

Greece | X | X |

Hungary | X | X |

Ireland | X | X |

Italy | | X |

Latvia | X | X |

Lithuania | X | X |

Luxembourg | X | X |

Malta | X | X |

Netherlands | X | X |

Poland | X | X |

Portugal | X | |

Romania | X | X |

Slovakia | X | X |

Slovenia | X | X |

Spain | X | X |

Sweden | X | X |

United Kingdom | X | X |

Table 5

Long-acting beta agonist bronchodilators

Country | Formoterol | Salmeterol |

Austria | X | X |

Belgium | X | X |

Bulgaria | X | X |

Cyprus | X | X |

Czech Republic | X | X |

Denmark | X | X |

Estonia | X | X |

Finland | X | X |

France | X | X |

Germany | X | X |

Greece | X | X |

Hungary | X | X |

Ireland | X | X |

Italy | X | X |

Latvia | X | X |

Lithuania | X | X |

Luxembourg | X | X |

Malta | X | X |

Netherlands | X | X |

Poland | X | X |

Portugal | X | X |

Romania | X | X |

Slovakia | X | X |

Slovenia | X | X |

Spain | X | X |

Sweden | X | X |

United Kingdom | X | X |

Table 6

Combinations of active ingredients in a single MDI

Country | | |

Austria | X All products | |

Belgium | X All products | |

Bulgaria | X All products | |

Cyprus | | |

Czech Republic | X All products | |

Denmark | X All products | |

Estonia | | |

Finland | X All products | |

France | X All products | |

Germany | X All products | |

Greece | | |

Hungary | X All products | |

Ireland | | |

Italy | Budesonide + Fenoterol | Fluticasone + Salmeterol |

Latvia | X All products | |

Lithuania | X All products | |

Luxembourg | X All products | |

Malta | X All products | |

Netherlands | X All products | |

Poland | X All products | |

Portugal | X All products | |

Romania | X All products | |

Slovakia | X All products | |

Slovenia | X All products | |

Spain | | |

Sweden | X All products | |

United Kingdom | | |

--------------------------------------------------

ANNEX II

ESSENTIAL MEDICAL USES

Quota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:

Chiesi Farmaceutici SpA (IT)

Valeas SpA Pharmaceuticals (IT)

(VARI) SpA — LINDAL Group Italia (IT)

--------------------------------------------------

ANNEX III

ESSENTIAL LABORATORY AND ANALYTICAL USES

Quota of controlled substances of Group I and II that may be used for essential laboratory and analytical uses, are allocated to:

Carlo Erba Réactifs-SDS (FR)

CNRS — Groupe de physique des solides (FR)

Harp International (UK)

Honeywell Specialty Chemicals (DE)

Ineos Fluor (UK)

LGC Standards (DE)

Mallinckrodt Baker (NL)

Merck KGaA (DE)

Mikro + Polo (SI)

Panreac Química (ES)

Sigma Aldrich Chimie (FR)

Sigma Aldrich Company (UK)

Sigma Aldrich Logistik (DE)

Tazzetti Fluids (IT)

--------------------------------------------------

ANNEX IV

ESSENTIAL LABORATORY AND ANALYTICAL USES

Quota of controlled substances of Group III that may be used for essential laboratory and analytical uses are allocated to:

Airbus France (FR)

Ineos Fluor (UK)

Ministry of Defence (NL)

--------------------------------------------------

ANNEX V

ESSENTIAL LABORATORY AND ANALYTICAL USES

Quota of controlled substances of Group IV that may be used for essential laboratory and analytical uses, are allocated to:

Acros Organics (BE)

Carlo Erba Réactifs-SDS (FR)

Honeywell Specialty Chemicals (DE)

Institut Scientifique du Service Publique (BE)

Mallinckrodt Baker (NL)

Merck KGaA (DE)

Mikro + Polo (SI)

Panreac Quimica (ES)

Sigma Aldrich Chimie (FR)

Sigma Aldrich Company (UK)

Sigma Aldrich Laborchemikalien (DE)

Sigma Aldrich Logistik (DE)

VWR ISAS (FR)

--------------------------------------------------

ANNEX VI

ESSENTIAL LABORATORY AND ANALYTICAL USES

Quota of controlled substances of Group V that may be used for essential laboratory and analytical uses are allocated to:

Acros Organics (BE)

Merck KGaA (DE)

Mikro + Polo (SI)

Panreac Química (ES)

Sigma Aldrich Chimie (FR)

Sigma Aldrich Company (UK)

Sigma Aldrich Logistik (DE)

--------------------------------------------------

ANNEX VII

LABORATORY AND ANALYTICAL CRITICAL USES

Quota of controlled substances of Group VI that may be used for laboratory and analytical critical uses are allocated to:

Sigma Aldrich Chimie (FR)

Sigma Aldrich Company (UK)

Sigma Aldrich Logistik (DE)

--------------------------------------------------

ANNEX VIII

ESSENTIAL LABORATORY AND ANALYTICAL USES

Quota of controlled substances of Group VII that may be used for essential laboratory and analytical uses are allocated to:

Ineos Fluor (UK)

Sigma Aldrich Logistik (DE)

Solvay Organics (DE)

--------------------------------------------------

ANNEX IX

ESSENTIAL LABORATORY AND ANALYTICAL USES

Quota of controlled substances of Group IX that may be used for essential laboratory and analytical uses are allocated to:

Ineos Fluor (UK)

Sigma Aldrich Chimie (FR)

Sigma Aldrich Company (UK)

Sigma Aldrich Logistik (DE)

--------------------------------------------------

ANNEX X

This Annex is not published because it contains confidential commercial information.

--------------------------------------------------